Japanese encephalitis (JE) virus is a member of the Flaviviridue and causes human central nervous system disease.
Infections with JE virus are a significant cause of mortality and morbidity in many areas of the world, especially in Southeast Asia. Clinically overt JE infection causes fever, headache, and impaired consciousness that results in death in 5â€"20%of patients and in permanent neurologic impair ment for many survivors.1-2 Infection with JE virus stimu lates a strong humoral immune response: the detection of immunoglobulin M (IgM) to JE virus or a significant in crease in the titer of total antibody to JE virus is the labo ratory criterion most often used for diagnosis of infection. Although humoral immunity to JE virus has been extensive ly studied in humans, cellular immunity has not.
Cellular immunity against infection with flaviviruses has been studied using dengue.3 9 Murray Valley encephalitis,7-10 Kunjin,"~" and West Nile viruses.6" Reports on JE virus using a mouse model revealed the presence of T suppressor cells,14-'6 T helper cells,6 and B memory lymphocytes. 17 However, there have been no reports of human T lymphocyte responses to JE vaccination or infection.
Currently, the only JE vaccine approved for humans is a formalin-inactivated virion preparation purified from JE vi rus-infected mouse brains.1* Although this inactivated vac cine has been demonstrated to be safe and effective,19 it is expensive and has been occasionally associated with serious adverse reactions.2" Recombinant poxviruses encoding the premembrane (prM) and envelope (E) genes of JE virus have been developed as a candidate second generation JE vaccine to address the limitations of existing products. 21 24 The recombinant poxviruses elicited high levels of protective an tibodies to JE virus in mice. The antibody responses of these recombinant poxviruses correlated with their ability to in duce the synthesis of extracellular particles (EPs) in tissue culture cells. Furthermore, these EPs, which are virus-like membrane vesicles containing prM, membrane (M). and E proteins, are immunogenic and protective in mice,24-25and could be considered for use as a subunit vaccine. To increase their safety, our second generation JE vaccine candidates were based on a highly attenuated vaccinia virus strain23 or a canarypox strain. 24 Effective evaluation of these vaccine candidates in hu mans will require information on human T cell responses against JE virus. In this paper we analyze JE virus-specific T lymphocytes in peripheral blood mononuclear cells (PBMC) from patients recovering from JE and vaccinÃ©es who had received the commercially available inactivated vaccine. The PBMC from the JE-immune donors prolifer ated in vitro after stimulation with JE viral antigens, and the proliferating cells included CD4* and CDS* T lymphocytes.
The T cells from some vaccinÃ©es also responded to the EPs that contained prM/M and E proteins. This report presents the first information on JE virus-specific human T lympho cytes.
MATERIALS AND METHODS
Human PBMC. The peripheral blood specimens were ob tained from three different groups. The first group consisted of seven adult American vaccinÃ©es(designated VU1 to VU7) who had been immunized three or more times with the formalin-inactivated JE vaccine (Biken vaccine)18 within the past five years prior to the time of the study and who resided in the United States, where JE virus is absent. The second group consisted of three adult Japanese vaccinÃ©es (designated VJ1 to VJ3) who had been vaccinated during their childhood, had been given booster vaccinations within the previous five years, and had resided in no other area endemic for JE except Japan. One Japanese vaccinÃ©e(VJ1) provided two specimens: the first (VJ1-1) was a baseline sample, and the second (VJI-2) was collected one week after a booster vaccination. The third group consisted of seven Thai patients (designated PT1 to PT7) who survived an ep isode of JE defined by the presence of fever, impaired con sciousness, and detection of IgM antibodies to JE virus in the acute cerebrospinal fluid.26-27Their blood samples were collected from one to seven months after the onset of the disease. The control PBMC specimens were collected from two cord blood samples (designated CB1 and CB2) supplied by the University of Massachusetts Medical Center. The PBMC were separated by Ficoll-Hypaque density gradient centrifugation as previously described,4 resuspended at a concentration of 1 X lOVml in RPMI 1640 medium con taining 10% fetal bovine serum and 10% dimethylsulfoxide, and cryopreserved in liquid nitrogen until use.
Viruses. The Nakayama strain of JE virus28was prepared in an Aedes albopictus cell line (C6/36),29 which was ob tained from the American Type Culture Collection (Rockville, MD). A recombinant vaccinia virus encoding the prM and E genes of the Nakayama strain of JE virus, vP829,22 and its parent virus, vP410,2' have been previously de scribed.
Viral antigens. Live virus, fixed lysate of cells infected with JE virus and purified EPs were used as viral antigens in PBMC proliferation assays. Culture fluid of C6/36 cells infected with JE virus at a multiplicity of infection (MOI) of five and incubated at 28Â°Cfor 48 hr was used as the live virus antigen (virus titer of approximately 2 X 10s plaqueforming units/ml). The fixed cell lysate was prepared from cells infected with JE virus essentially as described. 4 Briefly, Vero cells were infected with JE virus at an MOI of five, incubated at 37Â°Cfor 24 hr, fixed in 0.025% glutaraldehyde, sonicated, and clarified. The EPs were purified from culture fluid of HeLa cells infected with vP829 as described. 25 The amounts of the JE virus E protein contained in the fixed cell lysate and the EP antigens were 4 u.g/ml and 30 |JLg/ml,re spectively, as estimated by Coomassie blue and immunochemical staining. Control antigens for the live virus and infected cell lysate consisted of uninfected C6/36 cell culture fluid and uninfected Vero cell lysate. Control preparations for the EP antigen were prepared from the culture fluid of cells infected with vP410 by the same procedure used to purify the EPs. Radioimmunoprecipitation (RIP). Serum or plasma specimens obtained from PBMC donors were tested for their ability to immunoprecipitate "S-labeled viral proteins har vested from the lysate of JE virus-infected cells as previ ously described.21
Proliferation assay of PBMC. Proliferative responses of PBMC were measured as previously described. 4 The PBMC (2 X IO5) were cultured with different dilutions of each of the viral and control antigens in 0.2 ml of AIM V medium (GIBCO BRL, Gaithersburg, MD) containing 10% human AB serum (Hazleton Research Products, Inc., Lenexa, KS) in 96-well V-bottom microplates (Costar, Cambridge, MA) at 37Â°C.Based on the results of previous experiments, the cell lysate was used at 1:20, 1:100, and 1:500 dilutions, live virus was used at 1:4, 1:8, and 1:16 dilutions, and EP was used at 1:10, 1:50, and 1:250 dilutions. Six days after ad dition of antigen, cells were pulsed with 1 u,Ci of tritiated (3H) thymidine for 18 hr before being harvested using a multiharvester (Titertek, Skatron Inc., Sterling, VA), and 3H-thymidine incorporation was determined by liquid scintilla tion counting (1205 Betaplate; Pharmacia, Wallac Oy, Fin land). To improve the specific proliferative responses of PBMC, T cell growth factor (TCGF; T-stim Culture Supple ment; Collaborative Biomedicai Products, Bedford, MA) was added to the PBMC from Thai patients, which had a lower degree of viability at a final concentration of 1% or 10% six days after antigen addition except for those of PT2. Stimulation indices were calculated by the standard formula: count per minute (cpm) induced by JE antigen divided by cpm induced by control antigen at the same dilution. The criteria to determine positive responses were 1) a stimulation index equal to or greater than 2.7 and 2) a total cpm obtained with viral antigens greater than 500. A stimulation index equal to or greater than 2.7 was considered as a positive proliferation response, since the maximum value of the stim ulation index of cord blood lymphocytes (for each concen tration of antigens) plus 1.96 times the standard error of the mean was 2.68.
Phenotypic analysis. The T lymphocyte depletion test was performed using anti-CD4 and anti-CD8 monoclonal antibodies (OKT4 and OKT8; Ortho Diagnostic Systems, Inc., Raritan, NJ) as described. 9 Briefly, approximately 1 x IO6 PBMC stimulated with the lysate at a 1:20 dilution or the virus at a 1:4 dilution were incubated with antibody at a 1:11 dilution at 4Â°Cfor 30 min, treated with rabbit com plement (Cedarlane Laboratories, Hornby, Ontario, Canada) at a 1:5 dilution at 37Â°Cfor 1 hr, and then used in prolif eration assays. The incorporation of 3H-thymidine was com pared with that obtained with cells treated with mouse IgG and complement. The percentage of the cells surviving after depletion treatment (as shown by staining with the mono clonal antibody used for depletion) had been demonstrated to be less than 3% in previous experiments.
RESULTS
Antibody status. Figure 1 shows the RIP results of serum or plasma specimens obtained from patients and vaccinÃ©es. All the patients showed strong reactions to the E protein of JE virus, and eight of 10 vaccinÃ©eshad detectable antibody against the E protein. The specific reaction of one Japanese vaccinÃ©e (VJ1-1) against E protein was not detectable on this autoradiograph, but the specimen taken from the same in dividual one week after vaccination (VJ1-2) showed a faint band, as did VU4. The specimens from VU2 and VJ2 did not show any detectable reactions against the E protein.
Patients had antibodies against nonstructural protein 1 (NS1) and NS3 of JE virus, but American vaccinÃ©es did not have antibodies against these nonstructural proteins. This difference was anticipated since nonstructural proteins of JE virus are excluded from the vaccine during its purification. One of three Japanese vaccinÃ©es(VJ3) had low levels of anti-NSl and anti-NS3 antibodies that were only visible with longer exposure of the gel used to produce the autoradiographs shown in Figure 1 .
Proliferative responses of PBMC. The results of the pro liferation assays of PBMC obtained from seven American vaccinÃ©esand two cord blood samples are shown in Table  1 . Positive responses against viral antigens were observed in three vaccinÃ©es(VU1, VU3, and VU6), and the PBMC of these three donors responded to all three antigen prepara- 
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FIGUREI. Japanese encephalitis (JE) virusâ€" specific reactivity of sera or plasma obtained from American vaccinÃ©es (VU 1 to VU7), Japanese vaccinÃ©es (VJl-1 to VJ3), and Thai patients (PT1 to PT7). These specimens were tested for their ability to immunoprecipitate radiolabeled proteins harvested from JE virus-infected cells. The positions of JE virus proteins are shown on the left side of the autoradiograph. E = envelope protein; NS1 and NS3 = nonstructural proteins; NSI' = a higher molecular weight form of NSI produced by alternative processing of the sequences encoded by the NS2A region of the JE virus genome.30 lions: JE virus-infected cell lysate, live virus, and ER The antigen dose that provided the maximum stimulation index varied in different donors. Proliferation assays of PBMC from three Japanese vaccinÃ©esshowed that PBMC of two donors (VJ1-2 and VJ3) responded to the lysate and PBMC of the donor VJ3 also responded to the virus (Table 2) ; how ever, none of these three Japanese vaccinÃ©esshowed re sponses to EP.
Proliferative responses of PBMC from Thai JE patients are shown in Table 3 . Since recovery of these PBMC sam ples from cryopreservation was lower than with other PBMC samples, TCGF was added to the PBMC culture at a final concentration of 10% or 1% on day 6 to amplify the re sponse in all assays except for those of PT2. Six of seven patients showed responses to the lysate antigens, and five patients showed responses to the live virus. The PBMC of four patients (PT1, PT2, PT3, and PT5) also responded to the lysate and JE virus without addition of TCGF. No pa tients showed responses against the EP.
Phenotypic analysis of cells responding to antigens. To characterize the proliferating cells, we depleted specific T lymphocyte populations from the PBMC using monoclonal antibodies and complement before 'H-thymidine incorpora tion (Table 4) cyte populations in PBMC that proliferated in responses to the lysate and live virus included both CD4* T lymphocytes and CDS* T lymphocytes in patients and vaccinÃ©es.The percent decrease in stimulation by lysate after treatment with anti-CD4 and complement was almost twice as great as that after treatment with anti-CD8 and complement, indicating that JE virus-specific CD4+ lymphocytes were more preva lent ( Table 4 ). The relative percent decreases achieved by treatments with anti-CD4 or anti-CD8 and complement were similar after stimulation with JE virus (Table 4) .
DISCUSSION
This report describes the detection in vaccinÃ©esand re covered patients of antibodies to both structural and nonstructural proteins of JE virus and JE virus-specific T mem ory lymphocytes. The results are summarized in Table 5 . Our preliminary characterization of T lymphocyte prolifer ative responses establishes another outcome measure with which to evaluate the possible effectiveness of a candidate second generation vaccine. The 92% efficacy of the first gen- eration vaccine was demonstrated in a field trial in Thailand; 19therefore, a placebo-controlled trial of any new JE vaccine would be unethical. Evidence of vaccine efficacy will be based on protection studies in animals and on surrogate re sponses of volunteers to vaccination. The ability of vaccine to elicit neutralizing antibody is one candidate surrogate marker. The ability of vaccine to elicit T cell responses is also proposed as a new candidate marker. Specifically. T cell proliferation responses would be advantageous to evaluate recipients of live recombinant vaccine candidates, since in general, cytotoxic T lymphocytes can be induced by infec tion with live viruses in contrast to immuni/.ation with pro teins or peptides; therefore, T lymphocyte proliferative re sponsiveness does not always correlate with antibody.
The presence of antibodies to nonstructural proteins of JE virus distinguished individuals infected with JE virus from those immunized with an inactivated whole virion vaccine. All seven patients recovering from the disease had antibod ies to NS1 and NS3: in contrast, none of seven American vaccinÃ©eshad those antibodies. These findings indicate that during infection with JE virus, the immune system, including T lymphocytes, encounters both structural and nonstructural virus protein antigens, but that during vaccination with in activated vaccine, T lymphocytes encounter only structural virus protein antigens. Therefore, it is likely that the single Japanese vaccinÃ©e(VJ3) who had anti-NSl and anti-NS3 antibodies was naturally and asymptomatically infected with JE virus in an endemic area (Japan). The presence of anti bodies to nonstructural proteins in a vaccinÃ©e with detectable levels of neutralizing antibody is consistent with our previ ous experiments in mice, which showed that animals with high titers of neutralizing antibody that were protected against lethal challenge produced antibodies to nonstructural proteins. 22 Japanese encephalitis virus-specific T lymphocytes were detected in donors infected with JE virus or immunized with the inactivated JE vaccine. The presence of specific lympho cytes was shown in proliferation assays using several dif ferent antigens. It is of interest that the responses of PBMC against EPs were observed with specimens from American vaccinÃ©esbut not with specimens from donors who were infected with JE virus and have antibody to nonstructural proteins. Similarly, a Japanese vaccinÃ©e who had antibodies against nonstructural protein (VJ3) did not respond to EPs (Table 5 ). The immunogens encountered by the vaccinÃ©es were limited to the structural proteins of JE virus, while those encountered by patients would have included both structural and nonstructural proteins produced in vivo during virus replication. Detection of T memory cells that respond to structural protein in PBMC of the vaccinÃ©esis consistent with immunization with noninfectious JE virus particles. We also expected to find T memory lymphocytes specific for the structural proteins of JE virus in PBMC of the patients, since the structural proteins induced a strong antibody response in these individuals. However, we did not detect any prolifer ation of T lymphocytes in PBMC of JE patients after in vitro stimulation with EPs. These results suggest that JE virusspecific T cells in JE patients respond mainly to nonstruc tural proteins or capsid (C) protein, and the levels of T mem ory cells that respond to E and prM/M proteins are undetectably low. On the other hand, the results may be second ary to the concentration of EPs used as the stimulating an tigens.
It is important to determine which proteins of JE virus are recognized by T cells from vaccinÃ©esand infected individ uals to help ensure induction of T cell immunity in vacci nÃ©es, and to help determine differences in T cell responses of patients during JE infection. Vaccinia expression systems have been used extensively to determine specific viral anti gens involved in immune recognition of many viruses, in cluding flaviviruses, in mice." l3 However, our earlier at tempts to determine specific antigens of JE virus in human PBMC using vaccinia-based recombinants" failed because of high responses of human PBMC against vaccinia antigens contained in the cell preparations. However, using the puri fied EPs, we were able to identify T cells with specific reac tivity to prM/M and E.
It is generally accepted that in vivo proliferation of human leukocyte antigen (HLA) class I-restricted, CDS* T lym phocytes tend to be stimulated by antigen presenting cells (APC) infected with live agents and HLA class II-restricted, CD4* T lymphocytes tend to be stimulated by APC sensi tized with noninfectious proteins. We detected the prolifer ation of both CD4* and CD8+ T cells in PBMC from two donors (PT5 and VJ3). These two donors had antibodies to NS1 and NS3, indicating that they had been infected with JE virus in the past. The presence of JE virus-specific CD4+ and CD8+ T memory cells in PBMC of PT5 and VJ3 is consistent with a history of JE virus infections.
In conclusion, we have demonstrated JE virus-specific proliferation of both CD4* and CDS* T lymphocytes in PBMC from patients and some vaccinÃ©es. The PBMC from some vaccinÃ©es did not proliferate, which is consistent with low levels of T memory cells induced by the commercially available inactivated JE vaccine. It is important to determine the functions of these CD4* and CD8+ T cells, e.g., cytotoxic functions and lymphokine production, and to define the protein(s) and epitope(s) recognized by these T cells. High levels of proliferation in vitro will make it possible for us to further characterize JE virus-specific T lymphocytes. The improved understanding of JE virusâ€"specificT lymphocytes may have important implications for the treatment of JE in fection and for the development of new vaccines that are safe and effective.
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